On March, 19 IMV Inc. (IMV) Analysts See $-0.07 EPS

On March, 19. Investors expect IMV Inc. (NASDAQ:IMV) to reveal its quarterly earnings, according to RTT. After $-0.11 EPS was published last quarter, analysts now see EPS growth of -36.36 % for IMV Inc.. IMV is touching $4.04 during the last trading session, after decreased 1.46%.IMV Inc. has volume of 2,382 shares. Since March 18, 2018 IMV has declined 20.90% and is downtrending. The stock underperformed the S&P 500 by 25.27%.

IMV Inc., a clinical-stage company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer.The firm is worth $204.09 million. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.Currently it has negative earnings. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer.

For more IMV Inc. (NASDAQ:IMV) news released briefly go to: Pehub.com, Businesswire.com, Nasdaq.com, Streetinsider.com or Benzinga.com. The titles are as follows: “Fonds de solidarité FTQ puts $5 mln more to work in IMV – PE Hub” released on March 11, 2019, “IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference – Business Wire” on March 07, 2019, “IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares – Nasdaq” with a publish date: February 28, 2019, “Form 6-K IMV Inc. For: Mar 07 – StreetInsider.com” and the last “81 Biggest Movers From Friday – Benzinga” with publication date: March 04, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.